ASCO 2014 | 50th Annual Meeting Overview and Highlights

Over 30,000 physicians, researchers and healthcare professionals from over 100 countries attended this year the 50th annual meeting of ASCO – the American Society of Clinical Oncology, which was held at the McCormick Convention center ?in Chicago, Ill.

Focusing on opportunities for the community of clinicians and researchers to lead all of society in the quest for knowledge and insight, the theme of this year’s annual meeting was “Science & Society: The Next 50 Years.”

This year, a record 5,530 abstracts were submitted. More than 2,900 abstracts were selected for presentation in Oral Abstract Sessions, Clinical Science Symposia, or Poster Sessions, confirming the robustness of clinical cancer research and the exciting advances occurring in labs and practices across the world. In addition to this huge volume of abstracts, more than 2,200 abstracts were selected for online publication.

A competitive year
According to 2013-2014 Chair of ASCO?s Scientific Program Committee Jedd D. Wolchok, MD, PhD, Chief, Melanoma and Immunotherapeutics Service and Lloyd J. Old Chair for Clinical Investigation, at Memorial Sloan Kettering Cancer Center, this year was a very competitive year. “In addition to a record-breaking number of abstracts submitted, we had to make sure that we selected the most current, cutting-edge science that is also of the highest quality. This is what our members and attendees have come to expect from the ASCO Annual Meeting.?

Overview & Highlights


  • Dutch Oncologist Receives Prestigious Karnofsky Memorial Award [Article]

Sunday, June 1, 2014

  • Study Shows First-Line Treatment with Bevacizumab + Chemotherapy and Cetuximab + Chemotherapy Offer Similar Survival Benefit for Patients with Metastatic Colorectal Cancer [Article]
  • Men with Metastatic, Hormone-Sensitive Prostate Cancer Benefit from Initial Hormone Therapy + Docetaxel [Article]
  • In Young Women with Hormone-sensitive, Early-stage Breast Cancer, Adjuvant Exemestane is more Effective than Tamoxifen when Combined with Ovarian Function Suppression [Article]

Monday, June 2, 2014

  • Adjuvant Ipilimumab Offers Promising Treatment for Patients with High-Risk Stage III Melanoma [Article]
  • Large Phase I Study Shows PD-1 Targeting Antibody MK-3475 has High and Long-lasting Activity Against Metastatic Melanoma [Article]
  • New First-in-class Targeted Drug Lenvatinib Delays Progression in Radioiodine-resistant, Advanced Differentiated Thyroid Cancer [Article]
  • Ramucirumab + Standard Docetaxel Extends Survival in Second Line for Patients with Advanced Non-Small Cell Lung Cancer [Article]
  • Reducing the Frequency of Zoledronic Acid is Safe and Offers Comparable Efficacy in Women with Breast Cancer and Bone Metastases, Compared to Standard Therapy [Article]
  • Combination of Targeted Drugs May Significantly Increase Progression-Free Survival in Women with Recurrent Ovarian Cancer, Study Shows [Article]

Tuesday, June 3, 2014

  • Study Confirms Ibrutinib Significantly Delays Disease Progression and Extends Survival for Patients with Resistant or Relapsed CLL [Article]
  • Discontinuing Certain Medications at End of Life May Improve a Patient’s Health Related Quality of Life [Article]
  • Some Patients with HPV-positive Oropharyngeal Cancer may benefit from Lower-does Radiation Therapy [Article]
  • Proof-of-Principal of Experimental Personalized Strategy for Advanced Cervical Cancer Shows Striking Results [Article]
  • Study Confirms Goserelin Helps Preserve Fertility Among Women Receiving Chemotherapy for Hormone Receptor-negative Breast Cancer [Article]
  • SAR3419 Achieved Objective Responses Well Above Study Threshold and was Found to Have a Favorable Safety Profile in Diffuse Large B-Cell Lymphoma – ADC Review/Journal of Antibody-drug Conjugates [Article]


  • Independent Study Shows Clinical Outcomes of Patients Assessed with both MammaPrint and Oncotype DX [Article]

Copyright ? 2014 InPress Media Group/Sunvalley Communication. All rights reserved. Republication or redistribution of InPress Media Group/Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of?InPress Media Group/Sunvalley Communication. InPress Media Group/Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.